Skip to content
Hemispherx Biopharma, Inc. Logo
  • COMPANY
  • PRODUCTS
  • R & D
    • Product Candidates Overview
    • Pipeline
    • Orphan Drug Designations
  • PARTNERING
  • INVESTOR RELATIONS
    • Press Releases
    • Events & Presentations
    • Stock Information
    • SEC Filings
    • XBRL Filings
    • Stockholder Meeting
    • Corporate Governance
    • Email Alerts
    • Investor Contact
  • BLOG
  • CONTACT

Press Releases

 
Nov 02, 2022
AIM ImmunoTech Receives Orphan Drug Designation for Ampligen (rintatolimod) for the Treatment of Ebola Virus Disease

Oct 31, 2022
Delaware Court Rules in Favor of AIM ImmunoTech and Declines to Declare Activist Group's Nominations Valid

Oct 26, 2022
AIM ImmunoTech Board Issues Letter to Shareholders

Oct 12, 2022
AIM ImmunoTech Announces FDA Clearance of IND Application to Evaluate Ampligen in Phase 2 Clinical Study for the Treatment of Post-COVID Conditions

Sep 21, 2022
AIM ImmunoTech to Present at the Virtual Investor Long COVID Event

Sep 19, 2022
AIM ImmunoTech Board Files Definitive Proxy Statement and Sends Letter to Shareholders

Sep 07, 2022
AIM ImmunoTech to Present at the H.C. Wainwright 24th Annual Global Investment Conference

Sep 06, 2022
AIM ImmunoTech Selected to Present at the 2nd Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care

Aug 30, 2022
AIM ImmunoTech and Study Collaborator Roswell Park Commence Enrollment in an NCI-funded Phase 2 Clinical Trial Evaluating Ampligen® (rintatolimod) in Primary PD-1/PD-L1 Resistant Melanoma

Aug 18, 2022
AIM ImmunoTech Announces Commencement of Phase 2 Study of Ampligen® for the Treatment of Pancreatic Cancer

 1     2    3   4   5   6   7 
 <<   <   >   >> 
Hemispherx Biopharma, Inc. Logo White

Latest News

  • CEO Roadshow Interviews Hemispherx Thomas K. Equels
  • Introducing You to the First Ampligen Quarterly Update
  • Proactive Investors USA Sits Down with Hemispherx CEO Thomas K. Equels

Privacy / Terms of Use

  • Terms Of Use
  • Investor Contact

Tweets by AIM Immuno

© Copyright | All Rights Reserved | AIM ImmunoTech Inc. | Privacy Policy | Terms of Use
FacebookTwitterYouTubeLinkedIn

Privacy
Resize Viewer - Reduce Resize Viewer - Expand Close window